Pa. Attorney General Sunday Backs Federal Rule for PBM Transparency
Pennsylvania’s attorney general joins 44 states calling for federal transparency requirements targeting pharmacy benefit managers accused of driving up drug costs.
HARRISBURG, PENNSYLVANIA — Pennsylvania Attorney General Dave Sunday joined 44 other attorneys general nationwide in supporting a proposed federal rule requiring greater transparency from Pharmacy Benefit Managers regarding their revenue sources.
The proposed rule from the U.S. Department of Labor would mandate more transparency from PBMs managing healthcare plans provided by employers. Approximately 136 million Americans receive coverage through employer-sponsored health plans.
PBM Role Under Scrutiny
PBMs serve as middlemen in the pharmaceutical industry and have faced increasing scrutiny from lawmakers, regulators, and critics for their alleged role in driving up drug costs. Originally created to help insurance providers process prescription drug claims, PBMs have expanded their operations significantly over recent decades.
These companies now create formularies, which are lists of drugs covered by insurance plans, and negotiate rebates and reimbursements with drug manufacturers. They also handle reimbursements to pharmacies when patients pick up covered prescriptions, with their contracts determining payment amounts for specific medications.
Industry Concentration Concerns
The three largest PBMs in the country manage approximately 80 percent of all prescription drug claims. Each of these major PBMs operates under parent companies that also own major insurance and pharmacy companies, creating significant industry concentration.
Critics have accused PBMs of receiving kickbacks for recommending specific products and lacking transparency in their business practices, which could drive up insurance costs for employers. The proposed federal rule aims to address these transparency concerns by requiring disclosure of revenue sources.
Regulatory Response
The multistate attorney general letter supporting the proposed rule represents a coordinated effort to address what officials view as problematic practices within the pharmaceutical supply chain. The regulation would specifically target PBMs that manage healthcare plans for employer-sponsored coverage.
Sunday’s participation in the letter reflects Pennsylvania’s ongoing efforts to address healthcare costs and ensure transparency in pharmaceutical industry practices. The federal rule proposal follows years of criticism regarding PBM operations and their impact on drug pricing.
The proposed Department of Labor rule would require PBMs to provide detailed disclosures about their fee structures and revenue sources when managing employer-sponsored health plans, potentially affecting millions of Americans who receive healthcare coverage through their workplaces.
